# Empagliflozin-based Quadruple Therapy vs Basal Insulin-based Therapy

> **NCT05103306** · — · UNKNOWN · sponsor: **Chungbuk National University Hospital** · enrollment: 300 (estimated)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Empagliflozin 25 MG
- **DRUG:** INS

## Key facts

- **NCT ID:** NCT05103306
- **Lead sponsor:** Chungbuk National University Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-01
- **Primary completion:** 2022-12
- **Final completion:** 2022-12
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2022-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05103306

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05103306, "Empagliflozin-based Quadruple Therapy vs Basal Insulin-based Therapy". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05103306. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*